SARS-CoV-2/COVID-19 und neuromuskuläre Erkrankungen

Schoser, Benedikt G. H.; Baum, Patrick; Boentert, Matthias; Dillmann, K.; Emmer, Alexander; Knauß, Samuel; Enax-Krumova, Elena; Großkreutz, Julian; Güttsches, A.; Hellwig, Kerstin; Holzapfel, K.; Kornblum, Cornelia; Lehmann, Helmar C.; Melms, Arthur; Meyer, Tobias; Petri, S.; Pilgram, Lisa; Reiners, K.; Saak, A.; Schäfer, Jan Hendrik; Schmidt, J.; Schneider‐Gold, Christiane; Schons, Maximilian; Vorgerd, M.; Young, P. L.; Zierz, S.

doi:10.1007/s42451-020-00198-2

Cited by 4 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent clinical evidence shows that SARS-CoV-2 induces neuromuscular symptoms (Schoser et al 2020) with muscle pain and weakness and fatigue. In these patients, 11% revealed Table 2 Early neurological/psychiatric symptoms of patients with coronavirus/SARS-CoV-2 "Percentage of patients" is mentioned in only a few publications, while there are a number of reports mentioning symptoms appearing in SARS-CoV-2 patients…”

Section: Symptomologymentioning

confidence: 99%

“…Bohmwald et al ( 2018 ), Arbour et al ( 2000 ), Burks et al ( 1980 ), Hung et al ( 2003 ), Lau et al ( 2004 ), Yeh et al ( 2004 ), Li et al ( 2020a , b ), Poyladji et al ( 2020 ), Schoser et al ( 2020 )…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…In these patients, 11% revealed an increase of creatinkinase presenting with muscle weakness. Creatinkinase increased significantly with clinical severity from 22.4% in non-complicated patients to 71% of critically ill patients (Schoser et al 2020 ) (Table 2 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses

Riederer

Meulen

2020

J Neural Transm

View full text Add to dashboard Cite

While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood-brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore, long-term neurological as well as psychiatric symptomatology and eventual respective disorders cannot be excluded as evidenced from influenza-A triggered post-encephalitic Parkinsonism and HIV-1 triggered AIDS-dementia complex. From the available evidences for coronavirus-induced brain pathology, this review concludes a number of unmet needs for further research strategies like human postmortem brain analyses. SARS-CoV-2 mirroring experimental animal brain studies, characterization of time-dependent and region-dependent spreading behaviours of coronaviruses, enlightening of pathological mechanisms after coronavirus infection using long-term animal models and clinical observations of patients having had COVID-19 infection are calling to develop both protective strategies and drug discoveries to avoid early and late coronavirus-induced functional brain disturbances, symptoms and eventually disorders. To fight SARS-CoV-2, it is an urgent need to enforce clinical, molecular biological, neurochemical and genetic research including brain-related studies on a worldwide harmonized basis.

show abstract

Section: Symptomologymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses

Riederer

Meulen

2020

J Neural Transm

View full text Add to dashboard Cite

show abstract

“…Sekundäre Verschlechterungen neuromuskulärer Erkrankungen sind nur für die amyotrophe Lateralsklerose (ALS) und die Myasthenia gravis publiziert [ 125 ].…”

Section: Neuromuskuläre Erkrankungenunclassified

S1-Leitlinie: Neurologische Manifestationen bei COVID-19

Berlit

2020

DGNeurologie

View full text Add to dashboard Cite

Leitlinie der Deutschen Gesellschaft für Neurologie Einleitung Die Infektion mit dem neuen "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) führt zu einem bisher unbekannten Krankheitsbild, welches als COVID-19 ("COrona VIrus Disease 2019") bezeichnet wird und erstmalig in der Region Hubei in China beschrieben wurde. Die Infektion wurde durch die WHO am 11.03.2020 zur Pandemie erklärt. SARS-Fachgesellschaft Deutsche Gesellschaft für Neurologie in Zusammenarbeit mit der Deutschen Gesellschaft für Neurointensiv-und Notfallmedizin und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf-und Hals-Chirurgie

show abstract

Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report

saleh¹,

Jung²,

Tonner³

et al. 2021

J Med Case Reports

View full text Add to dashboard Cite

Background The symptoms of coronavirus disease 2019, caused by the novel severe acute respiratory syndrome coronavirus 2, were originally assumed to be mainly respiratory. With increasing knowledge, however, it turned out that the spectrum of complaints varies broadly with age and concomitant diseases. While many neurological symptoms were reported in the context of the disease, ranging from permanent fatigue to recurrent headaches and concentration disturbance, treatment approaches are still in development. This case discusses a possible treatment approach with immunoglobulin therapy and its outcomes. Case presentation We present the case of a 56-year-old Caucasian female patient who, following coronavirus disease 2019, developed peripheral sensory and autonomic disturbances that fell within subacute demyelinating neuropathy. Because a significant improvement in symptoms as well as in the results of clinical and electrophysiological examination was reported after immunoglobulin therapy, long-term therapy does not appear to be necessary. Conclusion Given the significant subjective and objective improvement reported, this case provides additional evidence that immunoglobulin therapy can be considered in post-coronavirus disease 2019 syndrome.

show abstract

SARS-CoV-2/COVID-19 und neuromuskuläre Erkrankungen

Cited by 4 publications

References 45 publications

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses

S1-Leitlinie: Neurologische Manifestationen bei COVID-19

Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report

Contact Info

Product

Resources

About